Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lifileucel (LN-144) in Metastatic Melanoma
NCT02360579Phase 2Completed
- Sponsor
- Iovance Biotherapeutics
- Start
- Sep 2015
- Primary completion
- Oct 2024
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 8
01
Overview
Phase 2, open-label trial of lifileucel in melanoma (4 cohorts), sponsored by Iovance Biotherapeutics. Primary endpoint: Objective Response Rate. Started Sep 2015; status: completed.
02
Drugs
lifileucel
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02360579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02360579.